SMO and chronic myelogenous leukemia, BCR-ABL1 positive: Whereas studies suggest that Smo targeting does not affect the engraftment potential and the fate decision of normal HSCs, it has been shown that it may potentially reduce the engraftment ability and the colony formation of CML LSCs.